{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T20:28:30Z","timestamp":1792528110680,"version":"4.5.0"},"reference-count":138,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,11,26]],"date-time":"2025-11-26T00:00:00Z","timestamp":1764115200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Triple-negative breast cancer (TNBC) remains a clinically aggressive subtype of breast cancer, defined by the absence of estrogen receptor, progesterone receptor, and HER2 amplification, and disproportionately affecting younger and racially diverse populations. Despite conventional chemotherapy, TNBC patients often face poor prognoses due to the lack of actionable molecular targets and early metastatic potential. Advances in molecular profiling have unveiled distinct TNBC subtypes and actionable vulnerabilities, including BRCA1\/2 mutations and PI3K\/AKT\/mTOR dysregulation. Therapies targeting DNA repair pathways, angiogenesis, and androgen receptor signaling\u2014particularly via PARP inhibitors and antibody\u2013drug conjugates like sacituzumab govitecan\u2014have demonstrated clinical benefit. Concurrently, TNBC\u2019s immunogenic nature, reflected in dense tumor-infiltrating lymphocytes (TILs), has driven the integration of immune checkpoint inhibitors. However, both primary and acquired resistance remain major barriers. This review delineates recent developments in targeted and immunotherapeutic strategies, emphasizing the role of TILs in shaping treatment response and highlighting combinatorial approaches that synergize molecular targeting with immunomodulation. Through a comprehensive understanding of TNBC\u2019s molecular and immune landscape, we propose new\u00a0therapeutic trajectories to improve clinical outcomes in this challenging malignancy.<\/jats:p>","DOI":"10.3389\/fimmu.2025.1711415","type":"journal-article","created":{"date-parts":[[2025,11,26]],"date-time":"2025-11-26T06:35:10Z","timestamp":1764138910000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":9,"title":["Integrating molecular targeting and immune modulation in triple-negative breast cancer: from mechanistic insights to therapeutic innovation"],"prefix":"10.3389","volume":"16","author":[{"given":"Yueren","family":"Fan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"He","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongyu","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tianfei","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yihang","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,11,26]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"105866","DOI":"10.1016\/j.humpath.2025.105866","article-title":"Tumor infiltrating lymphocytes in breast cancer: A narrative review with focus on analytic validity, clinical validity, and clinical utility","volume":"162","author":"Finkelman","year":"2025","journal-title":"Hum Pathol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.14740\/jmc5136","article-title":"Long durable response with trastuzumab deruxtecan monotherapy in a triple-negative metastatic breast cancer patient with human epidermal growth factor receptor 2 mutation: A long-term follow-up and literature review","volume":"16","author":"Idamakanti","year":"2025","journal-title":"J Med cases"},{"key":"B3","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/s40364-024-00715-5","article-title":"Histamine N-methyltransferase (HNMT) as a potential auxiliary biomarker for predicting adaptability to anti-HER2 drug treatment in breast cancer patients","volume":"13","author":"Cheng","year":"2025","journal-title":"biomark Res"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2025.1624870","article-title":"Expression of Insulin-like growth factor 2 mRNA-binding protein 3 and its diagnostic value in breast cancer","volume":"15","author":"Wang","year":"2025","journal-title":"Front Oncol"},{"key":"B5","doi-asserted-by":"publisher","first-page":"e42208","DOI":"10.1097\/MD.0000000000042208","article-title":"Preoperative inflammatory status as a positive prognostic factor for triple-negative breast cancer patients receiving neoadjuvant therapy","volume":"104","author":"Zhang","year":"2025","journal-title":"Med (Baltimore)"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1007\/s13691-021-00481-3","article-title":"HER2-positive breast cancer in a germline BRCA1 gene large deletion carrier","volume":"10","author":"Uchida","year":"2021","journal-title":"Int Cancer Conf J"},{"key":"B7","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1186\/s12885-025-14422-3","article-title":"Predictive value of androgen receptor in distant metastasis of triple-negative breast cancer: a retrospective multi-center study","volume":"25","author":"Zeng","year":"2025","journal-title":"BMC Cancer"},{"key":"B8","doi-asserted-by":"publisher","first-page":"6265","DOI":"10.3390\/ijms26136265","article-title":"Silibinin anticancer effects through the modulation of the tumor immune microenvironment in triple-negative breast cancer","volume":"26","author":"Mishra","year":"2025","journal-title":"Int J Mol Sci"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.2147\/BCTT.S516125","article-title":"Triple-negative breast cancer on the rise: breakthroughs and beyond","volume":"17","author":"Agelidis","year":"2025","journal-title":"Breast Cancer (Dove Med Press)"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2025.1602870","article-title":"Multiple drug resistance caused by germline mutation of exon 27 of BRCA2 gene in triple-negative breast cancer: a case report and literature review","volume":"15","author":"Li","year":"2025","journal-title":"Front Oncol"},{"key":"B11","doi-asserted-by":"publisher","first-page":"117160","DOI":"10.1016\/j.bcp.2025.117160","article-title":"A novel PARP-ATR dual inhibitor exhibits anti-triple-negative breast cancer activity by inducing excessive DNA damage in the mitotic phase","volume":"241","author":"Wang","year":"2025","journal-title":"Biochem Pharmacol"},{"key":"B12","doi-asserted-by":"publisher","first-page":"103834","DOI":"10.1016\/j.breast.2024.103834","article-title":"Olaparib monotherapy in advanced triple-negative breast cancer patients with homologous recombination deficiency and without germline mutations in BRCA1\/2: The NOBROLA phase 2 study","volume":"78","author":"Cort\u00e9s","year":"2024","journal-title":"Breast"},{"key":"B13","doi-asserted-by":"publisher","first-page":"113601","DOI":"10.1016\/j.jconrel.2025.113601","article-title":"Multifunctional nanoparticle-mediated targeting of metabolic reprogramming and DNA damage response pathways to treat drug-resistant triple-negative breast cancer","volume":"381","author":"Zhu","year":"2025","journal-title":"J Control Release"},{"key":"B14","doi-asserted-by":"publisher","first-page":"217865","DOI":"10.1016\/j.canlet.2025.217865","article-title":"The role of tumor microenvironment and immune cell crosstalk in triple-negative breast cancer (TNBC): Emerging therapeutic opportunities","volume":"628","author":"Sabit","year":"2025","journal-title":"Cancer Lett"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-24-2531","article-title":"Harnessing STING signaling and natural killer cells overcomes PARP inhibitor resistance in homologous recombination-deficient breast cancer","volume":"85","author":"Pedretti","year":"2025","journal-title":"Cancer Res"},{"key":"B16","doi-asserted-by":"publisher","first-page":"107554","DOI":"10.1016\/j.jbc.2024.107554","article-title":"Decrotonylation of cGAS K254 prompts homologous recombination repair by blocking its DNA binding and releasing PARP1","volume":"300","author":"Guo","year":"2024","journal-title":"J Biol Chem"},{"key":"B17","doi-asserted-by":"publisher","first-page":"103858","DOI":"10.1016\/j.dnarep.2025.103858","article-title":"Yin-Yang\u201d of PARP1 in genotoxic and inflammatory response","volume":"152","author":"Wang","year":"2025","journal-title":"DNA Repair (Amst)"},{"key":"B18","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1186\/s13045-025-01691-5","article-title":"The cGAS\u2013STING pathway in cancer immunity: mechanisms, challenges, and therapeutic implications","volume":"18","author":"Shen","year":"2025","journal-title":"J Hematol Oncol"},{"key":"B19","doi-asserted-by":"publisher","first-page":"794","DOI":"10.1016\/j.jconrel.2024.10.049","article-title":"Oxygen self-supplying nanoradiosensitizer activates cGAS-STING pathway to enhance radioimmunotherapy of triple negative breast cancer","volume":"376","author":"Wang","year":"2024","journal-title":"J Control Release"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-004280","article-title":"Cancer cell-autonomous overactivation of PARP1 compromises immunosurveillance in non-small cell lung cancer","volume":"10","author":"Juncheng","year":"2022","journal-title":"J Immunother Cancer"},{"key":"B21","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1158\/2159-8290.CD-23-0519","article-title":"NKG2A is a therapeutic vulnerability in immunotherapy resistant MHC-I heterogeneous triple-negative breast cancer","volume":"14","author":"Taylor","year":"2024","journal-title":"Cancer Discov"},{"key":"B22","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/j.omto.2021.05.006","article-title":"CD133 mRNA-transfected dendritic cells induce coordinated cytotoxic and helper T cell responses against breast cancer stem cells","volume":"22","author":"Tay","year":"2021","journal-title":"Mol Ther Oncolytics"},{"key":"B23","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1186\/s12885-025-14246-1","article-title":"Interplay of disulfidptosis and the tumor microenvironment across cancers: implications for prognosis and therapeutic responses","volume":"25","author":"Xu","year":"2025","journal-title":"BMC Cancer"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1507283","article-title":"CD8(+) T cell exhaustion in the tumor microenvironment of breast cancer","volume":"15","author":"Xie","year":"2024","journal-title":"Front Immunol"},{"key":"B25","doi-asserted-by":"publisher","first-page":"2523621","DOI":"10.1080\/15384047.2025.2523621","article-title":"IFN-\u03b3 downregulates miR-4319 to enhance NLRC5 and MHC-I expression in MHC-I-deficient breast cancer cells","volume":"26","author":"Zhao","year":"2025","journal-title":"Cancer Biol Ther"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1080\/02770903.2024.2403740","article-title":"Causal links between immune cells and asthma: Insights from a Mendelian Randomization analysis","volume":"62","author":"Xu","year":"2025","journal-title":"J Asthma"},{"key":"B27","doi-asserted-by":"publisher","first-page":"748","DOI":"10.3390\/cells14100748","article-title":"Cancer vulnerabilities through targeting the ATR\/chk1 and ATM\/chk2 axes in the context of DNA damage","volume":"14","author":"Fernandez","year":"2025","journal-title":"Cells"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1007\/s11596-024-2859-1","article-title":"DNA damage-driven inflammatory cytokines: reprogramming of tumor immune microenvironment and application of oncotherapy","volume":"44","author":"Wang","year":"2024","journal-title":"Curr Med Sci"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.21873\/anticanres.15593","article-title":"Characterization of cisplatin effects in lenvatinib-resistant hepatocellular carcinoma cells","volume":"42","author":"Hamaya","year":"2022","journal-title":"Anticancer Res"},{"key":"B30","doi-asserted-by":"publisher","first-page":"e2500035","DOI":"10.1200\/PO-25-00035","article-title":"Synthetic lethal co-mutations in DNA damage response pathways predict response to immunotherapy in pan-cancer","volume":"9","author":"Zhang","year":"2025","journal-title":"JCO Precis Oncol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.7150\/thno.101298","article-title":"Acylglycerol kinase inhibits macrophage anti-tumor activity via limiting mtDNA release and cGAS-STING-type I IFN response","volume":"15","author":"Du","year":"2025","journal-title":"Theranostics"},{"key":"B32","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1186\/s13045-019-0784-8","article-title":"Prospects for combining immune checkpoint blockade with PARP inhibition","volume":"12","author":"Li","year":"2019","journal-title":"J Hematol Oncol"},{"key":"B33","doi-asserted-by":"publisher","first-page":"5633","DOI":"10.3390\/cancers14225633","article-title":"Role of PARP inhibitors in cancer immunotherapy: potential friends to immune activating molecules and foes to immune checkpoints","volume":"14","author":"Franzese","year":"2022","journal-title":"Cancers (Basel)"},{"key":"B34","doi-asserted-by":"publisher","first-page":"2083755","DOI":"10.1080\/2162402X.2022.2083755","article-title":"PARP inhibition is a modulator of anti-tumor immune response in BRCA-deficient tumors","volume":"11","author":"Staniszewska","year":"2022","journal-title":"Oncoimmunology"},{"key":"B35","doi-asserted-by":"publisher","first-page":"114423","DOI":"10.1016\/j.biopha.2023.114423","article-title":"HIF-1\u03b1 inhibitor YC-1 suppresses triple-negative breast cancer growth and angiogenesis by targeting PlGF\/VEGFR1-induced macrophage polarization","volume":"161","author":"Li","year":"2023","journal-title":"BioMed Pharmacother"},{"key":"B36","doi-asserted-by":"publisher","first-page":"104740","DOI":"10.1016\/j.critrevonc.2025.104740","article-title":"PD-1\/PD-L1 inhibitors combined with anti-angiogenic drugs for advanced triple-negative breast cancer: Synergistic mechanisms and research progress","volume":"211","author":"Xu","year":"2025","journal-title":"Crit Rev Oncol Hematol"},{"key":"B37","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1007\/s10456-024-09965-1","article-title":"Clioquinol inhibits angiogenesis by promoting VEGFR2 degradation and synergizes with AKT inhibition to suppress triple-negative breast cancer vascularization","volume":"28","author":"Gu","year":"2025","journal-title":"Angiogenesis"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.5306\/wjco.v5.i2.125","article-title":"Systemic treatment strategies for triple-negative breast cancer","volume":"5","author":"Yadav","year":"2014","journal-title":"World J Clin Oncol"},{"key":"B39","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1038\/s41392-023-01460-1","article-title":"Angiogenic signaling pathways and anti-angiogenic therapy for cancer","volume":"8","author":"Liu","year":"2023","journal-title":"Signal Transduct Target Ther"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.00221","article-title":"Resistance mechanisms to anti-angiogenic therapies in cancer","volume":"10","author":"Haibe","year":"2020","journal-title":"Front Oncol"},{"key":"B41","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1186\/s40364-021-00312-w","article-title":"Antiangiogenic therapy reverses the immunosuppressive breast cancer microenvironment","volume":"9","author":"Chen","year":"2021","journal-title":"biomark Res"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2024-011314","article-title":"Bevacizumab, tislelizumab and nab-paclitaxel for previously untreated metastatic triple-negative breast cancer: a phase II trial","volume":"13","author":"Chen","year":"2025","journal-title":"J Immunother Cancer"},{"key":"B43","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1007\/s10637-023-01357-4","article-title":"Targeting chemotherapy resistance in mesenchymal triple-negative breast cancer: a phase II trial of neoadjuvant angiogenic and mTOR inhibition with chemotherapy","volume":"41","author":"Abuhadra","year":"2023","journal-title":"Invest New Drugs"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1007\/s10549-024-07308-8","article-title":"Racial disparities in outcomes of patients with stage I-III triple-negative breast cancer after adjuvant chemotherapy: a post-hoc analysis of the E5103 randomized trial","volume":"206","author":"Leonard","year":"2024","journal-title":"Breast Cancer Res Treat"},{"key":"B45","doi-asserted-by":"publisher","first-page":"365101","DOI":"10.1088\/1361-6528\/ab94dc","article-title":"Paclitaxel\/sunitinib-loaded micelles promote an antitumor response in vitro through synergistic immunogenic cell death for triple-negative breast cancer","volume":"31","author":"Qin","year":"2020","journal-title":"Nanotechnology"},{"key":"B46","doi-asserted-by":"publisher","first-page":"111760","DOI":"10.1016\/j.cellsig.2025.111760","article-title":"Apatinib combined with paclitaxel suppresses synergistically TNBC progression through enhancing ferroptosis susceptibility regulated SLC7A11\/GPX4\/ACSL4 axis","volume":"131","author":"Ma","year":"2025","journal-title":"Cell Signal"},{"key":"B47","doi-asserted-by":"publisher","first-page":"2232","DOI":"10.3390\/cancers17132232","article-title":"The PI3K\/akt\/mTOR signaling pathway in triple-negative breast cancer: A resistance pathway and a prime target for targeted therapies","volume":"17","author":"Hassan","year":"2025","journal-title":"Cancers (Basel)"},{"key":"B48","doi-asserted-by":"publisher","first-page":"112526","DOI":"10.1016\/j.isci.2025.112526","article-title":"STEAP3 promotes triple-negative breast cancer growth through the FGFR1-mediated activation of PI3K\/AKT\/mTOR signaling","volume":"28","author":"Yuan","year":"2025","journal-title":"iScience"},{"key":"B49","doi-asserted-by":"publisher","first-page":"111864","DOI":"10.1016\/j.cellsig.2025.111864","article-title":"MTDH\u03947-mediated mTOR activation drives doxorubicin resistance in triple-negative breast cancer: Relevance of mTORC1 inhibition on chemosensitization","volume":"132","author":"Sahoo","year":"2025","journal-title":"Cell Signal"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2025.03.001","article-title":"An open-label randomized active-controlled phase II clinical study to assess the efficacy and safety of afuresertib plus paclitaxel versus paclitaxel in patients with platinum-resistant ovarian cancer (PROFECTA-II\/GOG-3044)","volume":"194","author":"Herzog","year":"2025","journal-title":"Gynecol Oncol"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-24-2911","article-title":"Protein profiles predict treatment responses to the PI3K inhibitor umbralisib in patients with chronic lymphocytic leukemia","volume":"31","author":"Yin","year":"2025","journal-title":"Clin Cancer Res"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1016\/j.gendis.2022.10.021","article-title":"LRP1B suppresses HCC progression through the NCSTN\/PI3K\/AKT signaling axis and affects doxorubicin resistance","volume":"10","author":"Zhai","year":"2023","journal-title":"Genes Dis"},{"key":"B53","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1186\/s40364-023-00473-w","article-title":"HMGA1 augments palbociclib efficacy via PI3K\/mTOR signaling in intrahepatic cholangiocarcinoma","volume":"11","author":"Li","year":"2023","journal-title":"biomark Res"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.23.00059","article-title":"First-in-human, phase I dose-escalation and dose-expansion study of trophoblast cell-surface antigen 2-directed antibody-drug conjugate datopotamab deruxtecan in non-small-cell lung cancer: TROPION-panTumor01","volume":"41","author":"Shimizu","year":"2023","journal-title":"J Clin Oncol"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2202809","article-title":"Pembrolizumab plus chemotherapy in advanced triple-negative breast cancer","volume":"387","author":"Cortes","year":"2022","journal-title":"N Engl J Med"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.4103\/jcrt.jcrt_461_24","article-title":"Androgen receptor expression in triple negative breast cancer: A report from a tertiary care center","volume":"21","author":"Dogra","year":"2025","journal-title":"J Cancer Res Ther"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1002\/pros.24110","article-title":"Nivolumab plus ipilimumab, with or without enzalutamide, in AR-V7-expressing metastatic castration-resistant prostate cancer: A phase-2 nonrandomized clinical trial","volume":"81","author":"Shenderov","year":"2021","journal-title":"Prostate"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-013-3260-7","article-title":"Androgen receptor-positive triple negative breast cancer: a unique breast cancer subtype","volume":"21","author":"McGhan","year":"2014","journal-title":"Ann Surg Oncol"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-24-0559","article-title":"Androgen receptor inhibition increases MHC class I expression and improves immune response in prostate cancer","volume":"15","author":"Chesner","year":"2025","journal-title":"Cancer Discov"},{"key":"B60","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1038\/s41392-022-01042-7","article-title":"Targeting signaling pathways in prostate cancer: mechanisms and clinical trials","volume":"7","author":"He","year":"2022","journal-title":"Signal Transduct Target Ther"},{"key":"B61","doi-asserted-by":"publisher","first-page":"1972","DOI":"10.1016\/j.ccell.2023.10.006","article-title":"Anti-PD-1 immunotherapy with androgen deprivation therapy induces robust immune infiltration in metastatic castration-sensitive prostate cancer","volume":"41","author":"Hawley","year":"2023","journal-title":"Cancer Cell"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.5c01141","article-title":"Chirality-guided optimization of A(2A) adenosine receptor antagonists for enhanced metabolic stability and antitumor efficacy","volume":"68","author":"Ding","year":"2025","journal-title":"J Med Chem"},{"key":"B63","doi-asserted-by":"publisher","first-page":"15342","DOI":"10.3390\/ijms232315342","article-title":"Modulating the activity of androgen receptor for treating breast cancer","volume":"23","author":"You","year":"2022","journal-title":"Int J Mol Sci"},{"key":"B64","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1186\/s12964-025-02243-7","article-title":"C\/EBP\u03b2 increases tumor aggressiveness by enhancing KIFC1 expression in androgen receptor negative triple negative breast cancer","volume":"23","author":"Joshi","year":"2025","journal-title":"Cell Commun Signal"},{"key":"B65","doi-asserted-by":"publisher","first-page":"665","DOI":"10.3390\/cancers16030665","article-title":"MicroRNAs associated with androgen receptor and metastasis in triple-negative breast cancer","volume":"16","author":"Ahram","year":"2024","journal-title":"Cancers (Basel)"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1093\/oncolo\/oyad049","article-title":"Revisiting androgen receptor signaling in breast cancer","volume":"28","author":"Dai","year":"2023","journal-title":"Oncologist"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.2174\/1871520621666211201150818","article-title":"Is it time to consider the androgen receptor as a therapeutic target in breast cancer","volume":"22","author":"Forooshani","year":"2022","journal-title":"Anticancer Agents Med Chem"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(22)00367-1","article-title":"Abiraterone plus prednisone added to androgen deprivation therapy and docetaxel in de novo metastatic castration-sensitive prostate cancer (PEACE-1): a multicentre, open-label, randomised, phase 3 study with a 2\u2009\u00d7\u20092 factorial design","volume":"399","author":"Fizazi","year":"2022","journal-title":"Lancet"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.23.00041","article-title":"Darolutamide plus androgen-deprivation therapy and docetaxel in metastatic hormone-sensitive prostate cancer by disease volume and risk subgroups in the phase III ARASENS trial","volume":"41","author":"Hussain","year":"2023","journal-title":"J Clin Oncol"},{"key":"B70","doi-asserted-by":"publisher","first-page":"108253","DOI":"10.1016\/j.pharmthera.2022.108253","article-title":"Triple negative breast cancer (TNBC): Non-genetic tumor heterogeneity and immune microenvironment: Emerging treatment options","volume":"237","author":"So","year":"2022","journal-title":"Pharmacol Ther"},{"key":"B71","doi-asserted-by":"publisher","first-page":"107066","DOI":"10.1016\/j.compbiomed.2023.107066","article-title":"Integrated analysis of single-cell RNA-seq and bulk RNA-seq unravels T cell-related prognostic risk model and tumor immune microenvironment modulation in triple-negative breast cancer","volume":"161","author":"Guo","year":"2023","journal-title":"Comput Biol Med"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.923481","article-title":"Mapping the tumor microenvironment in TNBC and deep exploration for M1 macrophages-associated prognostic genes","volume":"13","author":"Xu","year":"2022","journal-title":"Front Immunol"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1263537","article-title":"Regulatory T cells are associated with the tumor immune microenvironment and immunotherapy response in triple-negative breast cancer","volume":"14","author":"Huang","year":"2023","journal-title":"Front Immunol"},{"key":"B74","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1007\/s00262-020-02669-7","article-title":"Integrated analysis of single-cell RNA-seq and bulk RNA-seq unravels tumour heterogeneity plus M2-like tumour-associated macrophage infiltration and aggressiveness in TNBC","volume":"70","author":"Bao","year":"2021","journal-title":"Cancer Immunol Immunother"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2024.3056","article-title":"Tumor-infiltrating lymphocytes in triple-negative breast cancer","volume":"331","author":"Leon-Ferre","year":"2024","journal-title":"Jama"},{"key":"B76","doi-asserted-by":"publisher","first-page":"704","DOI":"10.3390\/diagnostics10090704","article-title":"Prognostic role and clinical significance of tumor-infiltrating lymphocyte (TIL) and programmed death ligand 1 (PD-L1) expression in triple-negative breast cancer (TNBC): A systematic review and meta-analysis study","volume":"10","author":"Lotfinejad","year":"2020","journal-title":"Diagnostics (Basel)"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1513421","article-title":"Patterns of immune evasion in triple-negative breast cancer and new potential therapeutic targets: a review","volume":"15","author":"Serrano Garc\u00eda","year":"2024","journal-title":"Front Immunol"},{"key":"B78","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1007\/s13402-024-00992-0","article-title":"Unraveling Th subsets: insights into their role in immune checkpoint inhibitor therapy","volume":"48","author":"Ryba-Stanis\u0142awowska","year":"2025","journal-title":"Cell Oncol (Dordr)"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.1007\/s12094-021-02652-3","article-title":"Tumor microenvironment in triple-negative breast cancer: the correlation of tumor-associated macrophages and tumor-infiltrating lymphocytes","volume":"23","author":"Kuroda","year":"2021","journal-title":"Clin Transl Oncol"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-20-3773","article-title":"Tumor-infiltrating B lymphocyte profiling identifies igG-biased, clonally expanded prognostic phenotypes in triple-negative breast cancer","volume":"81","author":"Harris","year":"2021","journal-title":"Cancer Res"},{"key":"B81","doi-asserted-by":"publisher","first-page":"763","DOI":"10.3390\/biomedicines12040763","article-title":"Tumor-infiltrating lymphocytes (TILs) in breast cancer: prognostic and predictive significance across molecular subtypes","volume":"12","author":"Ciarka","year":"2024","journal-title":"Biomedicines"},{"key":"B82","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1038\/s41422-023-00909-w","article-title":"ZNF689 deficiency promotes intratumor heterogeneity and immunotherapy resistance in triple-negative breast cancer","volume":"34","author":"Ge","year":"2024","journal-title":"Cell Res"},{"key":"B83","doi-asserted-by":"publisher","first-page":"1060","DOI":"10.1016\/j.ccell.2022.07.005","article-title":"A covalent inhibitor of K-Ras(G12C) induces MHC class I presentation of haptenated peptide neoepitopes targetable by immunotherapy","volume":"40","author":"Zhang","year":"2022","journal-title":"Cancer Cell"},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1188831","article-title":"Chimeric RNAs reveal putative neoantigen peptides for developing tumor vaccines for breast cancer","volume":"14","author":"Mistretta","year":"2023","journal-title":"Front Immunol"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.636568","article-title":"Cancer immune evasion through loss of MHC class I antigen presentation","volume":"12","author":"DhatChinamoorthy","year":"2021","journal-title":"Front Immunol"},{"key":"B86","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1038\/s41467-024-54791-0","article-title":"Remodelling of the immune landscape by IFN\u03b3 counteracts IFN\u03b3-dependent tumour escape in mouse tumour models","volume":"16","author":"Lau","year":"2025","journal-title":"Nat Commun"},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.181.1.449","article-title":"Activation of the JAK\/STAT-1 signaling pathway by IFN-gamma can down-regulate functional expression of the MHC class I-related neonatal Fc receptor for IgG","volume":"181","author":"Liu","year":"2008","journal-title":"J Immunol"},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.1172\/JCI153167","article-title":"Histone methyltransferase WHSC1 loss dampens MHC-I antigen presentation pathway to impair IFN-\u03b3-stimulated antitumor immunity","volume":"132","author":"Ren","year":"2022","journal-title":"J Clin Invest"},{"key":"B89","doi-asserted-by":"publisher","first-page":"682","DOI":"10.3390\/cancers13040682","article-title":"Genomic landscape of hodgkin lymphoma","volume":"13","author":"Brune","year":"2021","journal-title":"Cancers (Basel)"},{"key":"B90","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1186\/s12929-021-00769-9","article-title":"Proteasome inhibitors restore the STAT1 pathway and enhance the expression of MHC class I on human colon cancer cells","volume":"28","author":"Liang","year":"2021","journal-title":"J BioMed Sci"},{"key":"B91","doi-asserted-by":"publisher","DOI":"10.1158\/2767-9764.CRC-21-0139","article-title":"Potent stimulation of the androgen receptor instigates a viral mimicry response in prostate cancer","volume":"2","author":"Alizadeh-Ghodsi","year":"2022","journal-title":"Cancer Res Commun"},{"key":"B92","doi-asserted-by":"publisher","DOI":"10.1080\/08830180902978120","article-title":"Molecular mechanisms of IFN-\u03b3 to up-regulate MHC class I antigen processing and presentation","volume":"28","author":"Zhou","year":"2009","journal-title":"Int Rev Immunol"},{"key":"B93","doi-asserted-by":"publisher","first-page":"365","DOI":"10.3390\/cells12030365","article-title":"Epigenetic perspective of immunotherapy for cancers","volume":"12","author":"Keshari","year":"2023","journal-title":"Cells"},{"key":"B94","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1325615","article-title":"Epigenetic modulation of antitumor immunity and immunotherapy response in breast cancer: biological mechanisms and clinical implications","volume":"14","author":"Yin","year":"2024","journal-title":"Front Immunol"},{"key":"B95","doi-asserted-by":"publisher","first-page":"12295","DOI":"10.3390\/ijms222212295","article-title":"Bridging radiotherapy to immunotherapy: the IFN-JAK-STAT axis","volume":"22","author":"Shi","year":"2021","journal-title":"Int J Mol Sci"},{"key":"B96","doi-asserted-by":"publisher","first-page":"6736","DOI":"10.3390\/ijms24076736","article-title":"Interferons and resistance mechanisms in tumors and pathogen-driven diseases-focus on the major histocompatibility complex (MHC) antigen processing pathway","volume":"24","author":"Massa","year":"2023","journal-title":"Int J Mol Sci"},{"key":"B97","doi-asserted-by":"publisher","DOI":"10.7150\/thno.68972","article-title":"FGFR blockade boosts T cell infiltration into triple-negative breast cancer by regulating cancer-associated fibroblasts","volume":"12","author":"Wu","year":"2022","journal-title":"Theranostics"},{"key":"B98","doi-asserted-by":"publisher","first-page":"101041","DOI":"10.1016\/j.jshs.2025.101041","article-title":"Exercise-induced extracellular vesicles delay tumor development by igniting inflammation in an immunologically cold triple-negative breast cancer mouse model","volume":"14","author":"Mlynska","year":"2025","journal-title":"J Sport Health Sci"},{"key":"B99","doi-asserted-by":"publisher","first-page":"3129","DOI":"10.3390\/cancers15123129","article-title":"GTN enhances antitumor effects of doxorubicin in TNBC by targeting the immunosuppressive activity of PMN-MDSC","volume":"15","author":"Mabrouk","year":"2023","journal-title":"Cancers (Basel)"},{"key":"B100","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1038\/s43018-020-00148-7","article-title":"Targeting immunosuppressive macrophages overcomes PARP inhibitor resistance in BRCA1-associated triple-negative breast cancer","volume":"2","author":"Mehta","year":"2021","journal-title":"Nat Cancer"},{"key":"B101","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1038\/s42003-023-04525-7","article-title":"Tissue-resident macrophages are major tumor-associated macrophage resources, contributing to early TNBC development, recurrence, and metastases","volume":"6","author":"Hirano","year":"2023","journal-title":"Commun Biol"},{"key":"B102","doi-asserted-by":"publisher","DOI":"10.2147\/JIR.S509245","article-title":"The role of PLIN3 in prognosis and tumor-associated macrophage infiltration: A pan-cancer analysis","volume":"18","author":"Yang","year":"2025","journal-title":"J Inflammation Res"},{"key":"B103","doi-asserted-by":"publisher","first-page":"e2104453119","DOI":"10.1073\/pnas.2104453119","article-title":"Expression of H(v)1 proton channels in myeloid-derived suppressor cells (MDSC) and its potential role in T cell regulation","volume":"119","author":"Alvear-Arias","year":"2022","journal-title":"Proc Natl Acad Sci U.S.A"},{"key":"B104","doi-asserted-by":"publisher","first-page":"217111","DOI":"10.1016\/j.canlet.2024.217111","article-title":"Intratumoral injection of mRNA encoding survivin in combination with STAT3 inhibitor stattic enhances antitumor effects","volume":"598","author":"Li","year":"2024","journal-title":"Cancer Lett"},{"key":"B105","doi-asserted-by":"publisher","DOI":"10.1097\/CMR.0000000000000721","article-title":"Neem leaf glycoprotein salvages T cell functions from Myeloid-derived suppressor cells-suppression by altering IL-10\/STAT3 axis in melanoma tumor microenvironment","volume":"31","author":"Sarkar","year":"2021","journal-title":"Melanoma Res"},{"key":"B106","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1182\/blood.2023022738","article-title":"Platelet-derived TGF-\u03b21 induces functional reprogramming of myeloid-derived suppressor cells in immune thrombocytopenia","volume":"144","author":"Wang","year":"2024","journal-title":"Blood"},{"key":"B107","doi-asserted-by":"publisher","first-page":"e37060","DOI":"10.1016\/j.heliyon.2024.e37060","article-title":"Eliminating a barrier: Aiming at VISTA, reversing MDSC-mediated T cell suppression in the tumor microenvironment","volume":"10","author":"Deng","year":"2024","journal-title":"Heliyon"},{"key":"B108","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.975261","article-title":"Role of myeloid-derived suppressor cells in the formation of pre-metastatic niche","volume":"12","author":"Ya","year":"2022","journal-title":"Front Oncol"},{"key":"B109","doi-asserted-by":"publisher","first-page":"893","DOI":"10.3390\/cells10040893","article-title":"New insights into the multifaceted role of myeloid-derived suppressor cells (MDSCs) in high-grade gliomas: from metabolic reprograming, immunosuppression, and therapeutic resistance to current strategies for targeting MDSCs","volume":"10","author":"Lakshmanachetty","year":"2021","journal-title":"Cells"},{"key":"B110","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.1023023","article-title":"Arginase-1 targeting peptide vaccine in patients with metastatic solid tumors - A phase I trial","volume":"13","author":"Lorentzen","year":"2022","journal-title":"Front Immunol"},{"key":"B111","doi-asserted-by":"publisher","first-page":"14248","DOI":"10.1038\/s41598-024-65129-7","article-title":"Chemotherapy-induced high expression of IL23A enhances efficacy of anti-PD-1 therapy in TNBC by co-activating the PI3K-AKT signaling pathway of CTLs","volume":"14","author":"Pan","year":"2024","journal-title":"Sci Rep"},{"key":"B112","doi-asserted-by":"publisher","first-page":"3826","DOI":"10.3390\/cells11233826","article-title":"Dying of stress: chemotherapy, radiotherapy, and small-molecule inhibitors in immunogenic cell death and immunogenic modulation","volume":"11","author":"Fabian","year":"2022","journal-title":"Cells"},{"key":"B113","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1678907","article-title":"Antibody-drug conjugates as immuno-oncology agents in colorectal cancer: targets, payloads, and therapeutic synergies","volume":"16","author":"Wang","year":"2025","journal-title":"Front Immunol"},{"key":"B114","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2024.02.002","article-title":"Event-free survival by residual cancer burden with pembrolizumab in early-stage TNBC: exploratory analysis from KEYNOTE-522","volume":"35","author":"Pusztai","year":"2024","journal-title":"Ann Oncol"},{"key":"B115","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2023.5033","article-title":"Clinical and biomarker findings of neoadjuvant pembrolizumab and carboplatin plus docetaxel in triple-negative breast cancer: neoPACT phase 2 clinical trial","volume":"10","author":"Sharma","year":"2024","journal-title":"JAMA Oncol"},{"key":"B116","doi-asserted-by":"publisher","first-page":"1843","DOI":"10.3390\/biomedicines10081843","article-title":"The generation of dual-targeting fusion protein PD-L1\/CD47 for the inhibition of triple-negative breast cancer","volume":"10","author":"Bian","year":"2022","journal-title":"Biomedicines"},{"key":"B117","doi-asserted-by":"publisher","first-page":"3379","DOI":"10.1038\/s41598-024-54041-9","article-title":"Immunological characterization of a long-lasting response in a patient with metastatic triple-negative breast cancer treated with PD-1 and LAG-3 blockade","volume":"14","author":"Rivoltini","year":"2024","journal-title":"Sci Rep"},{"key":"B118","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2021.02.029","article-title":"Caloric Restriction Impairs Regulatory T cells Within the Tumor Microenvironment After Radiation and Primes Effector T cells","volume":"110","author":"Manukian","year":"2021","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"B119","doi-asserted-by":"publisher","first-page":"114988","DOI":"10.1016\/j.intimp.2025.114988","article-title":"ISLR knockdown enhances radiotherapy-induced anti-tumor immunity by disrupting the Treg-mregDC-lymphoid niche in triple-negative breast cancer","volume":"161","author":"Wang","year":"2025","journal-title":"Int Immunopharmacol"},{"key":"B120","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1001\/jamaoncol.2022.5228","article-title":"Avelumab plus talazoparib in patients with advanced solid tumors: the JAVELIN PARP medley nonrandomized controlled trial","volume":"9","author":"Yap","year":"2023","journal-title":"JAMA Oncol"},{"key":"B121","doi-asserted-by":"publisher","first-page":"e2200446","DOI":"10.1200\/PO.22.00446","article-title":"Targeted therapies and the evolving standard of care for triple-negative and germline BRCA1\/2-mutated breast cancers in the high-risk, early-stage setting","volume":"7","author":"Desai","year":"2023","journal-title":"JCO Precis Oncol"},{"key":"B122","doi-asserted-by":"publisher","first-page":"115545","DOI":"10.1016\/j.bcp.2023.115545","article-title":"Triple-negative breast cancer: epidemiology, molecular mechanisms, and modern vaccine-based treatment strategies","volume":"212","author":"Karim","year":"2023","journal-title":"Biochem Pharmacol"},{"key":"B123","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1186\/s12943-022-01515-x","article-title":"Engineered exosomes as an in situ DC-primed vaccine to boost antitumor immunity in breast cancer","volume":"21","author":"Huang","year":"2022","journal-title":"Mol Cancer"},{"key":"B124","doi-asserted-by":"publisher","first-page":"e1401","DOI":"10.1002\/cti2.1401","article-title":"Glycolipid-peptide conjugate vaccines elicit CD8(+) T-cell responses and prevent breast cancer metastasis","volume":"11","author":"Burn","year":"2022","journal-title":"Clin Transl Immunol"},{"key":"B125","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2023-007336","article-title":"Personalized neoantigen viro-immunotherapy platform for triple-negative breast cancer","volume":"11","author":"Brito Baleeiro","year":"2023","journal-title":"J Immunother Cancer"},{"key":"B126","doi-asserted-by":"publisher","first-page":"104494","DOI":"10.1016\/j.esmoop.2025.104494","article-title":"Immune-related adverse events are associated with better event-free survival in a phase I\/II clinical trial of durvalumab concomitant with neoadjuvant chemotherapy in early-stage triple-negative breast cancer","volume":"10","author":"Rios-Hoyo","year":"2025","journal-title":"ESMO Open"},{"key":"B127","doi-asserted-by":"publisher","DOI":"10.1080\/15384047.2018.1423919","article-title":"PD1 protein expression in tumor infiltrated lymphocytes rather than PDL1 in tumor cells predicts survival in triple-negative breast cancer","volume":"19","author":"Ren","year":"2018","journal-title":"Cancer Biol Ther"},{"key":"B128","doi-asserted-by":"publisher","DOI":"10.1080\/14712598.2019.1598372","article-title":"Defining the immunogram of breast cancer: a focus on clinical trials","volume":"19","author":"Tarantino","year":"2019","journal-title":"Expert Opin Biol Ther"},{"key":"B129","doi-asserted-by":"publisher","first-page":"1864","DOI":"10.3390\/cancers11121864","article-title":"Identifying biomarkers to pair with targeting treatments within triple negative breast cancer for improved patient stratification","volume":"11","author":"Tovey","year":"2019","journal-title":"Cancers (Basel)"},{"key":"B130","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.986903","article-title":"LAG-3(+) tumor-infiltrating lymphocytes ameliorates overall survival in triple-negative breast cancer patients","volume":"12","author":"Hu","year":"2022","journal-title":"Front Oncol"},{"key":"B131","doi-asserted-by":"publisher","DOI":"10.21873\/anticanres.15466","article-title":"Clinical significance of expression of immunoadjuvant molecules (LAG-3, TIM-3, OX-40) in neoadjuvant chemotherapy for breast cancer","volume":"42","author":"Asano","year":"2022","journal-title":"Anticancer Res"},{"key":"B132","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1186\/s12964-023-01455-z","article-title":"The immune checkpoint TIGIT\/CD155 promotes the exhaustion of CD8\u2009+\u2009T cells in TNBC through glucose metabolic reprogramming mediated by PI3K\/AKT\/mTOR signaling","volume":"22","author":"Huang","year":"2024","journal-title":"Cell Commun Signal"},{"key":"B133","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.1014904","article-title":"Different expression patterns of VISTA concurrent with PD-1, Tim-3, and TIGIT on T cell subsets in peripheral blood and bone marrow from patients with multiple myeloma","volume":"12","author":"Huang","year":"2022","journal-title":"Front Oncol"},{"key":"B134","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-021-02886-8","article-title":"TIGIT promotes CD8(+)T cells exhaustion and predicts poor prognosis of colorectal cancer","volume":"70","author":"Liang","year":"2021","journal-title":"Cancer Immunol Immunother"},{"key":"B135","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1186\/s13046-025-03394-8","article-title":"Reprogramming the breast tumor immune microenvironment: cold-to-hot transition for enhanced immunotherapy","volume":"44","author":"Imani","year":"2025","journal-title":"J Exp Clin Cancer Res"},{"key":"B136","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1038\/s41416-025-03013-5","article-title":"Macrophages suppress CD8\u2009+\u2009T cell cytotoxic function in triple negative breast cancer via VISTA","volume":"133","author":"Abudula","year":"2025","journal-title":"Br J Cancer"},{"key":"B137","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djz208","article-title":"Unraveling triple-negative breast cancer tumor microenvironment heterogeneity: towards an optimized treatment approach","volume":"112","author":"Bareche","year":"2020","journal-title":"J Natl Cancer Inst"},{"key":"B138","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1001\/jamaoncol.2018.4224","article-title":"Long-term clinical outcomes and biomarker analyses of atezolizumab therapy for patients with metastatic triple-negative breast cancer: A phase 1 study","volume":"5","author":"Emens","year":"2019","journal-title":"JAMA Oncol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1711415\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,26]],"date-time":"2025-11-26T06:35:11Z","timestamp":1764138911000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1711415\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,26]]},"references-count":138,"alternative-id":["10.3389\/fimmu.2025.1711415"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2025.1711415","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,26]]},"article-number":"1711415"}}